Kornimate/medical-research-clean huggingface dataset:
effectiveness of duspatalin® in patients with post-cholecystectomy gastrointestinal spasm

Conditions: Post-cholecystectomy Gastrointestinal Spasms

Summary: prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with duspatalin® 200mg bis in die = twice a day (bid) and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years to 65 years; * patients suffering from post-cholecystectomy gi-spasms in the last 3 months with symptom onset at least 6 months prior to inclusion and not requiring surgical treatment; * laparoscopic cholecystectomy between 6 months to 5 years before enrollment; * patients having been prescribed duspatalin® (mebeverine) 200 mg bid (bis in die = twice a day) in accordance with approved local label; * patient's written authorization to provide data for the program exclusion criteria: * general and specific contraindications to duspatalin® treatment according to the local label; * planned endoscopic retrograde cholangiopancreatography (ercp) and/or surgical treatment; * being currently treated or having been treated with duspatalin® within the 6 weeks prior to entering the program; * pregnancy or lactation; * other conditions that make patient participation impossible (by investigator judgment); * previous enrollment in the present program; * treatment with other antispasmodics, pain-medication (nonsteroidal anti-inflammatory drugs (nsaids), tramadol, etc.) within 2 weeks prior to inclusion into the observational study.

Keywords: duspatalin mebeverine cholecystectomy gastrointestinal spasm abdominal pain dyspepsia antispasmodics
culturally sensitive depression care management for latino primary care patients

Conditions: Depression

Summary: the purpose of this study is to determine whether telephonic depression care management can improve depression outcomes for latino primary care patients who are enrolled in medicaid and are receiving an antidepressant from their primary care doctor.


Eligibility criteria:
inclusion criteria: * latino * adult * received an antidepressant prescription from primary care provider * not current receiving care from behavioral health provider * diagnosis of major depression, minor depression, dysthymia, or significant depression symptoms * english or spanish speaking * member, neighborhood health plan of ri

Keywords: depression primary care latino telephone care management
presentation of protoscolexes and acephalocysts in the fibrous capsule area of the liver with echinococcosis

Conditions: Echinococcosis, Hepatic

Summary: the objective of the study is to determine the presence of germinal elements of echinococcosis in the liver parenchyma next to and in the thickness of the fibrous capsule of hydatid cysts.


Eligibility criteria:
inclusion criteria: * presence of primary or recurrent liver echinococcosis disease requiring surgical treatment * cyst diametr \>5 cm; * performing one of the surgical treatment of liver echinococcosis with intraoperative sampling of part of the fibrous capsule with or without adjacent liver tissue for research; * signed informed consent of patients for inclusion in the study; exclusion criteria: * liver echinococcosis with cysts less than 5 cm in diametr; * presence of severe concomitant disorders
disseminating public health evidence to support state health department prevention of cancer and other chronic diseases

Conditions: Information Dissemination; Evidence-Based Public Health

Summary: the purpose of this study is to identify and evaluate dissemination strategies to promote the uptake of evidence-based cancer and other chronic disease prevention among state-level public health practitioners. dissemination strategies such as multi-day in-person training workshops and electronic information exchange modalities are hypothesized to associate with improved access and use of public health evidence and organizational supports for program and policy decision making based on evidence-based public health.

evidence-based public health approaches to prevent cancer and other chronic diseases have been identified in recent decades and have the potential for high impact. yet barriers to implement prevention approaches persist as a result of multiple factors including lack of organizational support, limited resources, competing priorities, and limited skill among the public health workforce. the purpose of this study was to learn how best to promote the adoption of evidence based public health practice related to chronic disease prevention. this cluster randomized trial aimed to evaluate the dissemination of public health knowledge about evidence-based prevention of cancer and other chronic diseases and test receptivity and usefulness of dissemination strategies directed toward state health department chronic disease practitioners to enhance capacity and organizational support for evidence-based chronic disease prevention. twelve state health department chronic disease units were randomly selected and assigned to intervention or control. state health department staff and the university-based study team jointly identified, refined, and selected dissemination strategies. intervention strategies included multi-day in-person training workshops, remote telephone follow-up and technical assistance, supplemental brief remote trainings, and health department work unit procedural changes to support and strengthen evidence-based decision making. evaluation methods included pre-post surveys and structured qualitative phone interviews.

Eligibility criteria:
inclusion criteria: * state health department chronic disease units (cluster) in the united states and corresponding public health workforce (individuals within cluster) exclusion criteria: * state health department has received extensive technical assistance and training comparable to our intervention (dissemination activities) * origin state has no logical matching pair matched state based on state population size * origin state has the lowest excess burden of cancer and other chronic risk and disease * origin state health department has lowest or highest capacity for ebdm as determined from previous research

Keywords: information dissemination information sharing innovation diffusion public health practice evidence-based public health chronic disease prevention cancer prevention and control
metformin in psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: psoriatic arthritis (psa) is a systemic, inflammatory disease. the chronic inflammation in psa predisposes patients to the metabolic syndrome (mets). mets is associated with systemic inflammation and proinflammatory cytokines. clinical observations and experimental results argue for an anti-inflammatory and immunosuppressant property of met.

the chronic inflammatory nature of psoriasis and psa predisposes patients to cardiovascular diseases and metabolic syndrome (mets). mets is associated with systemic inflammation and proinflammatory cytokines.clinical observations and experimental results argue for an anti-inflammatory and immunosuppressant property of met. a randomized placebo-controlled trial was conducted to evaluate the efficacy and safety of metformin as add-on therapy to mtx compared to mtx after 24 weeks in patients with psa. the study randomized 56 patients with a diagnosis of psa . patients with a history of a cardiovascular event and diabetics were excluded. body mass index (bmi) and classic cardiovascular risk factors were recorded. blood samples were analysed for glucose, lipid profile, esr, hscrp, proinflammatory cytokines; tumour necrosis factor alpha (tnf-alpha), interleukin-6 (il-6) and il-17. the homeostasis model assessment model for insulin resistance (homa-ir) was used. the patients were randomized in a 1:1 ratio to receive 500mg/day retarded formulation of metformin (n=29) or placebo (n=29). continuation of stable doses of mtx (25mg/week), nsaids, and/or corticosteroids (prednisone \<10 mg/day) was permitted. metformin drug pause on the day of mtx was given. folic acid supplementation was given to both groups. the primary clinical endpoint was the acr 20% (acr20) response at 24 weeks. secondary endpoints included reduction in pasi score, health assessment questionnaire- disability index (haq-di) and psoriatic arthritis response criteria (psarc) score.

Eligibility criteria:
inclusion criteria: * psoriatic arthritis patients exclusion criteria: * other inflammatory conditions

Keywords: psoriatic arthritis inflammation metabolic syndrome metformin
implementing a low fodmap diet in irritable bowel syndrome patients

Conditions: IBS - Irritable Bowel Syndrome

Summary: researchers are trying to determine the best course of action regarding the dietary management with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (fodmap diet) for irritable bowel syndrome.

an analysis of different educational programs providing information on the low fodmap diet will be performed.

Eligibility criteria:
inclusion criteria: * adult subjects (18-75 years) seen in the primary care clinic or in the gastroenterology clinic at mayo clinic florida, who are diagnosed with ibs by rome iv criteria exclusion criteria: * subjects who have previously tried the low fodmap diet (whether successful or not) * current or recent (less than 4 weeks) opioid use * current or recent (less than 10 weeks) rifaximin use * inability to speak or read english * pregnancy and/or breast-feeding * medical or psychological issues that would prevent modifying their diet for 8 weeks.
safety and efficacy study of isolagen therapytm in treatment of facial wrinkles and creases

Conditions: Facial Wrinkles and Creases

Summary: the purpose of this study is to evaluate the safety profile and the treatment effect of autologous human fibroblasts and placebo when administered to facial wrinkles and creases


Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age * high investigator wrinkle severity assessment score * subject assessment of dissatisfaction of facial appearance * provide written informed consent and comply with the study requirements * negative pregnancy test at screening visit * healthy, non-scarred skin for biopsy exclusion criteria: * low investigator wrinkle severity assessment score * subject assessment of satisfaction of facial appearance * physical attributes which prevent the assessment or treatment of the facial wrinkles * treatment with an investigational product or procedure within 30 days or plans to participate in another clinical trial * previous treatment with isolagen therapy * history of active autoimmune disease or organ transplantation * diagnosis of cancer, receiving active treatment * history of pigmentary disorders which can affect the face * active or chronic skin disease * known genetic disorders affecting fibroblasts or collagen * active systemic infection * requires chronic antibiotic or steroidal therapy * use of certain cosmetic treatments \& procedures * use of systemic agents that increase bleeding or clotting, or disorders equated with these effects * pregnant or lactating women or women trying to become pregnant * known allergic reaction to components of study treatment and/or study injection procedure * excessive exposure to sun or sunburn in the post-auricular area * subject has any disorder that may prevent compliance * subject who is part of the study staff, a family member or friend
influence of semaglutide on pharmacokinetics and pharmacodynamics of warfarin and pharmacokinetics of metformin in healthy subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe and asia. the aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin and pharmacokinetics of metformin in healthy subjects.


Eligibility criteria:
inclusion criteria: * male and female, age between 18 and 55 years (both inclusive) at the time of signing informed consent * body mass index (bmi) between 23 and 30 kg/m\^2 (both inclusive) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearingpotential and not using adequate contraceptive methods for the duration of the trial and for 5 weeks following the last dose of semaglutide. adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner * any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases * use of prescription or non-prescription systemic or topical medicinal products (including routine or non-routine vitamins or herbal products, but excluding paracetamol and contraceptives) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to visit 2 * smoking, drug or alcohol abuse
psychosocial/behavioral intervention in post-stroke depression

Conditions: Stroke

Summary: the primary aim of this study is to determine the effect of a nurse-delivered psychosocial/behavioral intervention on reduction of depression in community dwelling post-stroke patients. we expect the combined behavioral and pharmacologic intervention to be more effective than pharmacotherapy alone in sustaining the improvement in depression for the experimental group. secondary aims are to examine the effect of the psychosocial/behavioral intervention time course and sustainability of response to treatment, effect on limitations in ability, limitation in participation and overall stroke impact in community-dwelling post-stroke patients, and to compare ischemic stroke survivors who are and are not depressed within the first four months following stroke by their 5-httlpr genotypes (s/s, s/l, or l/l).

150 patients at university of washington affiliated hospitals who are found to be depressed by dsmiv criteria within the first four months following ischemic stroke will be invited to join the study, and randomly assigned to a problem-solving/pleasant events intervention provided by an advanced practice nurse, or to regular clinic follow-up. both groups will receive standard antidepressant treatment and written materials from the american stroke association, and will be assessed for up to two years following the study. the primary outcome is reduction in depression at 12 months following stroke. secondary outcomes are reductions in limitations in activity (barthel index), reduction in limitation in participation (stroke impact scale) and overall stroke impact (stroke impact scale) at 6, 12, and 24 months post- stroke. we hypothesize that all patients will improve their mood and functional ability related to their post-stroke standard treatment, but that those who receive the psychosocial intervention will have significantly greater improvement in mood, functional ability, social participation, and less overall stroke impact at all follow-up measurement. a supplemental aim is to expand aim 4 of the parent study, adding sert genotype to our list of factors that might influence treatment outcome for psd. further, since we are screening both depressed and not depressed stroke survivors for this study, we will add a fifth aim: to compare ischemic stroke survivors who are and are not depressed within the first four months following stroke by their 5-httlpr genotypes (s/s, s/l, or l/l).

Eligibility criteria:
inclusion criteria: ischemic stroke within previous 4 months screens positive for depressive symptoms by geriatric depression scale able to provide informed consent - exclusion criteria: subarachnoid or intracranial hemorrhagic stroke global aphasia reduced level of consciousness (gcs \<15)

Keywords: depressive symptoms behavior and behavior mechanisms recovery
cervical cerclage position throughout the pregnancy.

Conditions: Cervix Uteri-Diseases

Summary: cervical cerclage is an obstetric intervention used in women with poor obstetric histories. after recruiting the participant, trans vaginal sonography will be used to examine cervical length and funneling. in addition vaginal examination will be performed to evaluate the cervix. after placing the cerclage, the participant will be invited every 4 weeks for a follow up evaluation session in order to examine the cervix and cerclage position. .

cervical cerclage is an obstetric intervention used in women with poor obstetric histories due to late abortions, premature deliveries and painless dilatation. these 3 situations are usually due to cervical incompetence though can be caused by infection and other factors. the cerclage is usually placed from 12-24 weeks of gestation depending on the indication and medical follow up during pregnancy. there are 2 methods for cerclage performance-mcdonald and shirodkar that have the same efficacy. after recruiting the participant, trans vaginal sonography will be used to examine cervical length and funneling. in addition vaginal examination will be performed to evaluate the cervix. after placing the cerclage, the participant will be invited every 4 weeks for a follow up evaluation session in order to examine the cervix and cerclage position. each follow up will include a vaginal examination and trans vaginal sonography. the trans vaginal sonography will examine total cervical length, funneling, and the cerclage's distance from the inner and outer os' of the cervix.

Eligibility criteria:
inclusion criteria: * women that have a cervical cerclage placed during pregnancy at the investigator's medical center. exclusion criteria: * women that do not require cervical cerclage. * women that had a cervical cerclage placed at a different medical center.
study to evaluate the efficacy and safety of dwp14012 in patients with acute or chronic gastritis

Conditions: Acute Gastritis; Chronic Gastritis

Summary: the purpose of study is to confirm the efficacy of dwp14012 x mg qd, dwp14012 y mg bid compared to placebo in patients with acute or chronic gastritis

this study was designed as a multi-center, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to assess the efficacy and safety of oral administration of dwp14012 x mg qd, y mg bid and placebo for 2 weeks in patients with acute and chronic gastritis.

Eligibility criteria:
inclusion criteria: * adults between 19 and 75 years old based on the date of written agreement * those who are diagnosed with acute or chronic gastritis with at least one erosion observed on upper gastrointestinal endoscopy * those who had experienced one or more subjective symptoms of gastritis exclusion criteria: * those who have had surgery to reduce gastric acid secretion, or gastric or esophageal surgery * those with history of clinically significant hepatic, renal, neurologic, pulmonary, endocrine, hematologic, cardiovascular or genitourinary disease that could affect the study results
analgesic effect between tap block and continuous wound infusion in abdominoplasty surgery

Conditions: Surgery of Abdominoplasty With Flank Liposuction

Summary: the purpose of this randomized controlled study is to compare the postoperative analgesic effect of a continuous wound infusion of local anesthetics and a sole transverse abdominal plan (tap) regional block in the surgery of abdominoplasty combined with flank liposuction. local anesthetics products used are ropivacaine combined with clonidine. similar amount of local anesthetics and clonidine are used.

in a first group, patients receive, after induction of anaesthesia and before surgery, a tap block (transverse abdominal plan block) with 3mg/kg ropivacaine 0.5% (maximum 200 mg) and 150 microg clonidine. in a second group, before skin closure, a multiholes catheter was inserted beyond the skin. 20 mg ropivacaine 0.2% added with 150 microg clonidine was injected as bolus dose through this catheter followed by a continuous infusion of ropivacaine 0.2% 10ml per hour during the following 9 hours (total dose of 200 mgr).

Eligibility criteria:
inclusion criteria: * patients scheduled for abdominoplasty combined with flank liposuction exclusion criteria: * allergy to local anesthetics or clonidine * coagulation disorders * history of chronic pain * alcohol or drugs dependance * refusal of the patients

Keywords: postoperative analgesia abdominoplasty continuous wound infusion transverse abdominal plan block local anesthetics : ropivacaine regional anesthesia
effect of different supralottic airway devicess on optic nerve sheath diameter

Conditions: Intracranial Pressure Increase; Supraglottic Airway Device; Optic Nerve Sheath Diameter

Summary: direct laryngoscopy and tracheal intubation are associated with increases in intraocular pressure (iop), intracranial pressure (icp), heart rate (hr), and blood pressure. the use of supraglottic airway devices (sads) are known to be beneficial in overcoming the disadvantages of laryngoscopy and tracheal intubation, especially ocular and pressure stress responses. in recent years, it has been reported that ultrasonographic measurement of optic nerve sheath diameter (onsd) can be used in the diagnosis of increased icp. the aim of our study is to compare the effects of proseal laryngeal mask airway (plma), suprem laryngeal mask airway (slma) and i-gel on hemodynamic response and onsd during insertion in adult patients.


Eligibility criteria:
inclusion criteria: * asa physical status of i-ii * elective surgery * non-ophthalmic procedures * 1-2 h duration * general anaesthesia * supine position exclusion criteria: * mallampati and asa status ≥iii, * a history or suspect of difficult airway, * previous intracranial/ocular surgery, * cerebral edema/high intracranial pressure, * glaucoma, * uncontrolled hypertension -, diabetic retinopathy, * obstetric patients, * those who refused to participate in the study

Keywords: supraglottic airway device hemodynamic response optic nerve sheath diameter